{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T01:52:33Z","timestamp":1793757153117,"version":"4.6.1"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T00:00:00Z","timestamp":1534464000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","award":["9883"],"award-info":[{"award-number":["9883"]}],"id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Fonds de Recherche du Quebec","award":["202685"],"award-info":[{"award-number":["202685"]}]},{"name":"Genome Canada and Quebec","award":["142HIV"],"award-info":[{"award-number":["142HIV"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Retrovirology"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12977-018-0440-3","type":"journal-article","created":{"date-parts":[[2018,8,17]],"date-time":"2018-08-17T11:56:29Z","timestamp":1534506989000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Selective resistance profiles emerging in patient-derived clinical isolates with cabotegravir, bictegravir, dolutegravir, and elvitegravir"],"prefix":"10.1186","volume":"15","author":[{"name":"the Montreal Primary HIV (PHI) Cohort Study Group","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maureen","family":"Oliveira","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruxandra-Ilinca","family":"Ibanescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Anstett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thibault","family":"M\u00e9spl\u00e8de","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Routy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjorie A.","family":"Robbins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2084-728X","authenticated-orcid":false,"given":"Bluma G.","family":"Brenner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,8,17]]},"reference":[{"key":"440_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3390\/v10010010","volume":"10","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Ibanescu RI, Hardy I, Roger M. Genotypic and phylogenetic insights on prevention of the spread of HIV-1 and drug resistance in \u201creal-world\u201d settings. Viruses. 2017;10:10.","journal-title":"Viruses"},{"key":"440_CR2","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1056\/NEJMra1004180","volume":"365","author":"MA Wainberg","year":"2011","unstructured":"Wainberg MA, Zaharatos GJ, Brenner BG. Development of antiretroviral drug resistance. N Engl J Med. 2011;365:637\u201346.","journal-title":"N Engl J Med"},{"key":"440_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.virusres.2016.07.006","volume":"239","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Wainberg MA. Clinical benefit of dolutegravir in HIV-1 management related to the high genetic barrier to drug resistance. Virus Res. 2017;239:1\u20139.","journal-title":"Virus Res"},{"key":"440_CR4","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12977-017-0360-7","volume":"14","author":"K Anstett","year":"2017","unstructured":"Anstett K, Brenner B, Mesplede T, Wainberg MA. HIV drug resistance against strand transfer integrase inhibitors. Retrovirology. 2017;14:36.","journal-title":"Retrovirology"},{"key":"440_CR5","doi-asserted-by":"publisher","first-page":"1853","DOI":"10.1097\/QAD.0000000000001590","volume":"31","author":"L Elzi","year":"2017","unstructured":"Elzi L, Erb S, Furrer H, Cavassini M, Calmy A, Vernazza P, Gunthard H, Bernasconi E, Battegay M. Swiss HIVCSG: adverse events of raltegravir and dolutegravir. AIDS. 2017;31:1853\u20138.","journal-title":"AIDS"},{"key":"440_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1016\/S0140-6736(07)60597-2","volume":"369","author":"B Grinsztejn","year":"2007","unstructured":"Grinsztejn B, Nguyen BY, Katlama C, Gatell JM, Lazzarin A, Vittecoq D, Gonzalez CJ, Chen J, Harvey CM, Isaacs RD. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet. 2007;369:1261\u20139.","journal-title":"Lancet"},{"key":"440_CR7","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1128\/JVI.01534-07","volume":"82","author":"K Shimura","year":"2008","unstructured":"Shimura K, Kodama E, Sakagami Y, Matsuzaki Y, Watanabe W, Yamataka K, Watanabe Y, Ohata Y, S Y, Sato M, et al. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303\/GS-9137). J Virol. 2008;82:764\u201374.","journal-title":"J Virol"},{"key":"440_CR8","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1128\/AAC.01075-09","volume":"54","author":"O Delelis","year":"2010","unstructured":"Delelis O, Thierry S, Subra F, Simon F, Malet I, Alloui C, Sayon S, Calvez V, Deprez E, Marcelin AG, et al. Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother. 2010;54:491\u2013501.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1177\/135965350901400108","volume":"14","author":"AI Maiga","year":"2009","unstructured":"Maiga AI, Malet I, Soulie C, Derache A, Koita V, Amellal B, Tchertanov L, Delelis O, Morand-Joubert L, Mouscadet JF, et al. Genetic barriers for integrase inhibitor drug resistance in HIV type-1 B and CRF02_AG subtypes. Antivir Ther. 2009;14:123\u20139.","journal-title":"Antivir Ther"},{"key":"440_CR10","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/QAD.0b013e32833cf265","volume":"24","author":"T Bar-Magen","year":"2010","unstructured":"Bar-Magen T, Donahue DA, McDonough EI, Kuhl BD, Faltenbacher VH, Xu H, Michaud V, Sloan RD, Wainberg MA. HIV-1 subtype B and C integrase enzymes exhibit differential patterns of resistance to integrase inhibitors in biochemical assays. AIDS. 2010;24:2171\u20139.","journal-title":"AIDS"},{"key":"440_CR11","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/jac\/dkp014","volume":"63","author":"I Malet","year":"2009","unstructured":"Malet I, Delelis O, Soulie C, Wirden M, Tchertanov L, Mottaz P, Peytavin G, Katlama C, Mouscadet JF, Calvez V, Marcelin AG. Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients. J Antimicrob Chemother. 2009;63:795\u2013804.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR12","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3109\/07853890.2014.883169","volume":"46","author":"T Mesplede","year":"2014","unstructured":"Mesplede T, Quashie PK, Zanichelli V, Wainberg MA. Integrase strand transfer inhibitors in the management of HIV-positive individuals. Ann Med. 2014;46:123\u20139.","journal-title":"Ann Med"},{"key":"440_CR13","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1016\/S0140-6736(17)32299-7","volume":"390","author":"J Gallant","year":"2017","unstructured":"Gallant J, Lazzarin A, Mills A, Orkin C, Podzamczer D, Tebas P, Girard PM, Brar I, Daar ES, Wohl D, et al. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial. Lancet. 2017;390:2063\u201372.","journal-title":"Lancet"},{"key":"440_CR14","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1016\/S0140-6736(17)31917-7","volume":"390","author":"DA Margolis","year":"2017","unstructured":"Margolis DA, Gonzalez-Garcia J, Stellbrink HJ, Eron JJ, Yazdanpanah Y, Podzamczer D, Lutz T, Angel JB, Richmond GJ, Clotet B, et al. Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial. Lancet. 2017;390:1499\u2013510.","journal-title":"Lancet"},{"key":"440_CR15","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","volume":"4","author":"PE Sax","year":"2017","unstructured":"Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154\u201360.","journal-title":"Lancet HIV"},{"key":"440_CR16","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1128\/AAC.01209-10","volume":"55","author":"M Kobayashi","year":"2011","unstructured":"Kobayashi M, Yoshinaga T, Seki T, Wakasa-Morimoto C, Brown KW, Ferris R, Foster SA, Hazen RJ, Miki S, Suyama-Kagitani A, et al. In Vitro antiretroviral properties of S\/GSK1349572, a next-generation HIV integrase inhibitor. Antimicrob Agents Chemother. 2011;55:813\u201321.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1517\/13543784.2011.562189","volume":"20","author":"JC Lenz","year":"2011","unstructured":"Lenz JC, Rockstroh JK. S\/GSK1349572, a new integrase inhibitor for the treatment of HIV: promises and challenges. Expert Opin Investig Drugs. 2011;20:537\u201348.","journal-title":"Expert Opin Investig Drugs"},{"key":"440_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.1517\/13543784.2010.501078","volume":"19","author":"N Prada","year":"2010","unstructured":"Prada N, Markowitz M. Novel integrase inhibitors for HIV. Expert Opin Investig Drugs. 2010;19:1087\u201398.","journal-title":"Expert Opin Investig Drugs"},{"key":"440_CR19","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700\u20138.","journal-title":"Lancet"},{"key":"440_CR20","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1128\/JVI.06591-11","volume":"86","author":"PK Quashie","year":"2012","unstructured":"Quashie PK, Mesplede T, Han YS, Oliveira M, Singhroy DN, Fujiwara T, Underwood MR, Wainberg MA. Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir. J Virol. 2012;86:2696\u2013705.","journal-title":"J Virol"},{"key":"440_CR21","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1742-4690-10-22","volume":"10","author":"T Mesplede","year":"2013","unstructured":"Mesplede T, Quashie PK, Osman N, Han Y, Singhroy DN, Lie Y, Petropoulos CJ, Huang W, Wainberg MA. Viral fitness cost prevents HIV-1 from evading dolutegravir drug pressure. Retrovirology. 2013;10:22.","journal-title":"Retrovirology"},{"key":"440_CR22","doi-asserted-by":"publisher","first-page":"2733","DOI":"10.1093\/jac\/dku199","volume":"69","author":"T Mesplede","year":"2014","unstructured":"Mesplede T, Osman N, Wares M, Quashie PK, Hassounah S, Anstett K, Han Y, Singhroy DN, Wainberg MA. Addition of E138K to R263K in HIV integrase increases resistance to dolutegravir, but fails to restore activity of the HIV integrase enzyme and viral replication capacity. J Antimicrob Chemother. 2014;69:2733\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR23","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1742-4690-11-7","volume":"11","author":"M Wares","year":"2014","unstructured":"Wares M, Mesplede T, Quashie PK, Osman N, Han Y, Wainberg MA. The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness. Retrovirology. 2014;11:7.","journal-title":"Retrovirology"},{"key":"440_CR24","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1097\/QAD.0000000000000752","volume":"29","author":"T Mesplede","year":"2015","unstructured":"Mesplede T, Quashie PK, Hassounah S, Osman N, Han Y, Liang J, Singhroy DN, Wainberg MA. The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B. AIDS. 2015;29:1459\u201366.","journal-title":"AIDS"},{"key":"440_CR25","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1093\/jac\/dkx118","volume":"72","author":"BG Brenner","year":"2017","unstructured":"Brenner BG, Ibanescu RI, Oliveira M, Roger M, Hardy I, Routy JP, Kyeyune F, Quinones-Mateu ME, Wainberg MA. Montreal PHICSG: HIV-1 strains belonging to large phylogenetic clusters show accelerated escape from integrase inhibitors in cell culture compared with viral isolates from singleton\/small clusters. J Antimicrob Chemother. 2017;72:2171\u201383.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR26","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1128\/JVI.03353-14","volume":"89","author":"PK Quashie","year":"2015","unstructured":"Quashie PK, Oliviera M, Veres T, Osman N, Han YS, Hassounah S, Lie Y, Huang W, Mesplede T, Wainberg MA. Differential effects of the G118R, H51Y, and E138K resistance substitutions in different subtypes of HIV integrase. J Virol. 2015;89:3163\u201375.","journal-title":"J Virol"},{"key":"440_CR27","doi-asserted-by":"publisher","first-page":"4552","DOI":"10.1128\/AAC.00157-11","volume":"55","author":"KE Hightower","year":"2011","unstructured":"Hightower KE, Wang R, Deanda F, Johns BA, Weaver K, Shen Y, Tomberlin GH, Carter HL 3rd, Broderick T, Sigethy S, et al. Dolutegravir (S\/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes. Antimicrob Agents Chemother. 2011;55:4552\u20139.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR28","doi-asserted-by":"publisher","first-page":"2810","DOI":"10.1093\/jac\/dkv176","volume":"70","author":"N Osman","year":"2015","unstructured":"Osman N, Mesplede T, Quashie PK, Oliveira M, Zanichelli V, Wainberg MA. Dolutegravir maintains a durable effect against HIV replication in tissue culture even after drug washout. J Antimicrob Chemother. 2015;70:2810\u20135.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR29","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(17)32340-1","volume":"390","author":"PE Sax","year":"2017","unstructured":"Sax PE, Pozniak A, Montes ML, Koenig E, DeJesus E, Stellbrink HJ, Antinori A, Workowski K, Slim J, Reynes J, et al. Coformulated bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection (GS-US-380-1490): a randomised, double-blind, multicentre, phase 3, non-inferiority trial. Lancet. 2017;390:2073\u201382.","journal-title":"Lancet"},{"key":"440_CR30","doi-asserted-by":"crossref","first-page":"7086","DOI":"10.1128\/AAC.01474-16","volume":"60","author":"M Tsiang","year":"2016","unstructured":"Tsiang M, Jones GS, Goldsmith J, Mulato A, Hansen D, Kan E, Tsai L, Bam RA, Stepan G, Stray KM, et al. Antiviral activity of bictegravir (GS-9883), a novel potent HIV-1 integrase strand transfer inhibitor with an improved resistance profile. Antimicrob Agents Chemother. 2016;60:7086\u201397.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR31","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s12977-018-0420-7","volume":"15","author":"SJ Smith","year":"2018","unstructured":"Smith SJ, Zhao XZ, Burke TR Jr, Hughes SH. Efficacies of cabotegravir and bictegravir against drug-resistant HIV-1 integrase mutants. Retrovirology. 2018;15:37.","journal-title":"Retrovirology"},{"key":"440_CR32","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1016\/S1473-3099(15)00152-8","volume":"15","author":"DA Margolis","year":"2015","unstructured":"Margolis DA, Brinson CC, Smith GHR, de Vente J, Hagins DP, Eron JJ, Griffith SK, Clair MHS, Stevens MC, Williams PE, et al. Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. Lancet Infect Dis. 2015;15:1145\u201355.","journal-title":"Lancet Infect Dis"},{"key":"440_CR33","doi-asserted-by":"publisher","first-page":"e154","DOI":"10.1016\/S2352-3018(17)30016-4","volume":"4","author":"PE Sax","year":"2017","unstructured":"Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, et al. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomised, double-blind, phase 2 trial. Lancet HIV. 2017;4:e154\u201360.","journal-title":"Lancet HIV"},{"key":"440_CR34","doi-asserted-by":"crossref","first-page":"1745","DOI":"10.1128\/JVI.64.4.1745-1755.1990","volume":"64","author":"F Boulerice","year":"1990","unstructured":"Boulerice F, Bour S, Geleziunas R, Lvovich A, Wainberg MA. High frequency of isolation of defective human immunodeficiency virus type 1 and heterogeneity of viral gene expression in clones of infected U-937 cells. J Virol. 1990;64:1745\u201355.","journal-title":"J Virol"},{"key":"440_CR35","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/jac\/dkw071","volume":"71","author":"BG Brenner","year":"2016","unstructured":"Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplede T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016;71:1948\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR36","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1093\/jac\/dkp182","volume":"64","author":"J Ghosn","year":"2009","unstructured":"Ghosn J, Mazet AA, Avettand-Fenoel V, Peytavin G, Wirden M, Delfraissy JF, Chaix ML. Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen. J Antimicrob Chemother. 2009;64:433\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR37","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1128\/AAC.01228-07","volume":"52","author":"I Malet","year":"2008","unstructured":"Malet I, Delelis O, Valantin MA, Montes B, Soulie C, Wirden M, Tchertanov L, Peytavin G, Reynes J, Mouscadet JF, et al. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro. Antimicrob Agents Chemother. 2008;52:1351\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR38","doi-asserted-by":"crossref","first-page":"1921","DOI":"10.1093\/jac\/dkv012","volume":"70","author":"F Danion","year":"2015","unstructured":"Danion F, Belissa E, Peytavin G, Thierry E, Lanternier F, Scemla A, Lortholary O, Delelis O, Avettand-Fenoel V, Duvivier C. Non-virological response to a dolutegravir-containing regimen in a patient harbouring a E157Q-mutated virus in the integrase region. J Antimicrob Chemother. 2015;70:1921\u20133.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR39","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3390\/v10010041","volume":"10","author":"C Charpentier","year":"2018","unstructured":"Charpentier C, Descamps D. Resistance to HIV integrase inhibitors: about R263K and E157Q mutations. Viruses. 2018;10:41.","journal-title":"Viruses"},{"key":"440_CR40","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1093\/jac\/dkx511","volume":"73","author":"C Charpentier","year":"2018","unstructured":"Charpentier C, Malet I, Andre-Garnier E, Storto A, Bocket L, Amiel C, Morand-Joubert L, Tumiotto C, Nguyen T, Maillard A, et al. Phenotypic analysis of HIV-1 E157Q integrase polymorphism and impact on virological outcome in patients initiating an integrase inhibitor-based regimen. J Antimicrob Chemother. 2018;73:1039\u201344.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR41","unstructured":"Dudas K DF, Wang R, Margolis D, Demarest J, Griffith S, St Clair MH. Characterization of NRTI and INI resistance mutations observed in a study subject on ral two-drug therapy with 10\u00a0mg cabotegravir and 25\u00a0mg rilpivirine. In: International workshop on antiretroviral drug resistance, 21\u201322 Feb 2015, Seattle, WA."},{"key":"440_CR42","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1097\/COH.0000000000000169","volume":"10","author":"DA Margolis","year":"2015","unstructured":"Margolis DA, Boffito M. Long-acting antiviral agents for HIV treatment. Curr Opin HIV AIDS. 2015;10:246\u201352.","journal-title":"Curr Opin HIV AIDS"},{"key":"440_CR43","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1097\/QAD.0000000000001726","volume":"32","author":"U Neogi","year":"2018","unstructured":"Neogi U, Singh K, Aralaguppe SG, Rogers LC, Njenda DT, Sarafianos SG, Hejdeman B, Sonnerborg A. Ex-vivo antiretroviral potency of newer integrase strand transfer inhibitors cabotegravir and bictegravir in HIV type 1 non-B subtypes. AIDS. 2018;32:469\u201376.","journal-title":"AIDS"},{"key":"440_CR44","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1128\/AAC.03909-14","volume":"59","author":"T Yoshinaga","year":"2015","unstructured":"Yoshinaga T, Kobayashi M, Seki T, Miki S, Wakasa-Morimoto C, Suyama-Kagitani A, Kawauchi-Miki S, Taishi T, Kawasuji T, Johns BA, et al. Antiviral characteristics of GSK1265744, an HIV integrase inhibitor dosed orally or by long-acting injection. Antimicrob Agents Chemother. 2015;59:397\u2013406.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR45","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.antiviral.2018.01.013","volume":"152","author":"T Yoshinaga","year":"2018","unstructured":"Yoshinaga T, Seki T, Miki S, Miyamoto T, Suyama-Kagitani A, Kawauchi-Miki S, Kobayashi M, Sato A, Stewart E, Underwood M, Fujiwara T. Novel secondary mutations C56S and G149A confer resistance to HIV-1 integrase strand transfer inhibitors. Antiviral Res. 2018;152:1\u20139.","journal-title":"Antiviral Res"},{"key":"440_CR46","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.1093\/jac\/dkw071","volume":"71","author":"BG Brenner","year":"2016","unstructured":"Brenner BG, Thomas R, Blanco JL, Ibanescu RI, Oliveira M, Mesplede T, Golubkov O, Roger M, Garcia F, Martinez E, Wainberg MA. Development of a G118R mutation in HIV-1 integrase following a switch to dolutegravir monotherapy leading to cross-resistance to integrase inhibitors. J Antimicrob Chemother. 2016;71:1948\u201353.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR47","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/S0140-6736(13)61221-0","volume":"382","author":"P Cahn","year":"2013","unstructured":"Cahn P, Pozniak AL, Mingrone H, Shuldyakov A, Brites C, Andrade-Villanueva JF, Richmond G, Buendia CB, Fourie J, Ramgopal M, et al. Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study. Lancet. 2013;382:700\u20138.","journal-title":"Lancet"},{"key":"440_CR48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1097\/QAD.0000000000001494","volume":"31","author":"KJ Lepik","year":"2017","unstructured":"Lepik KJ, Harrigan PR, Yip B, Wang L, Robbins MA, Zhang WW, Toy J, Akagi L, Lima VD, Guillemi S, et al. Emergent drug resistance with integrase strand transfer inhibitor-based regimens. AIDS. 2017;31:1425\u201334.","journal-title":"AIDS"},{"issue":"5","key":"440_CR49","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1093\/infdis\/jiy176","volume":"218","author":"IEA Wijting","year":"2018","unstructured":"Wijting IEA, Lungu C, Rijnders BJA, van der Ende ME, Pham HT, Mesplede T, Pas SD, Voermans JJC, Schuurman R, van de Vijver D, et al. HIV-1 resistance dynamics in patients failing dolutegravir maintenance monotherapy. J Infect Dis. 2018;218(5):688\u201397.","journal-title":"J Infect Dis"},{"key":"440_CR50","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1093\/infdis\/jiy186","volume":"218","author":"DR Kuritzkes","year":"2018","unstructured":"Kuritzkes DR. Resistance to dolutegravir\u2014a chink in the armor? J Infect Dis. 2018;218:673\u20135.","journal-title":"J Infect Dis"},{"key":"440_CR51","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1086\/315254","volume":"181","author":"PS Sullivan","year":"2000","unstructured":"Sullivan PS, Do AN, Ellenberger D, Pau CP, Paul S, Robbins K, Kalish M, Storck C, Schable CA, Wise H, et al. Human immunodeficiency virus (HIV) subtype surveillance of African-born persons at risk for group O and group N HIV infections in the United States. J Infect Dis. 2000;181:463\u20139.","journal-title":"J Infect Dis"},{"key":"440_CR52","doi-asserted-by":"crossref","first-page":"5870","DOI":"10.1016\/S0021-9258(18)60646-5","volume":"263","author":"T Haertle","year":"1988","unstructured":"Haertle T, Carrera CJ, Wasson DB, Sowers LC, Richman DD, Carson DA. Metabolism and anti-human immunodeficiency virus-1 activity of 2-halo-2\u2032,3\u2032-dideoxyadenosine derivatives. J Biol Chem. 1988;263:5870\u20135.","journal-title":"J Biol Chem"},{"key":"440_CR53","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/978-1-59745-170-3_29","volume":"485","author":"M Oliveira","year":"2009","unstructured":"Oliveira M, Brenner BG, Wainberg MA. Isolation of drug-resistant mutant HIV variants using tissue culture drug selection. Methods Mol Biol. 2009;485:427\u201333.","journal-title":"Methods Mol Biol"},{"key":"440_CR54","doi-asserted-by":"publisher","first-page":"6913","DOI":"10.1128\/JVI.07133-11","volume":"86","author":"MA Brockman","year":"2012","unstructured":"Brockman MA, Chopera DR, Olvera A, Brumme CJ, Sela J, Markle TJ, Martin E, Carlson JM, Le AQ, McGovern R, et al. Uncommon pathways of immune escape attenuate HIV-1 integrase replication capacity. J Virol. 2012;86:6913\u201323.","journal-title":"J Virol"},{"key":"440_CR55","doi-asserted-by":"publisher","first-page":"2493","DOI":"10.1093\/jac\/dkq379","volume":"65","author":"N Gonzalez","year":"2010","unstructured":"Gonzalez N, Perez-Olmeda M, Mateos E, Cascajero A, Alvarez A, Spijkers S, Garcia-Perez J, Sanchez-Palomino S, Ruiz-Mateos E, Leal M, Alcami J. A sensitive phenotypic assay for the determination of human immunodeficiency virus type 1 tropism. J Antimicrob Chemother. 2010;65:2493\u2013501.","journal-title":"J Antimicrob Chemother"},{"key":"440_CR56","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1093\/cid\/ciu019","volume":"58","author":"A Gonzalez-Serna","year":"2014","unstructured":"Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, Harrigan PR, Swenson LC. Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis. 2014;58:1165\u201373.","journal-title":"Clin Infect Dis"},{"key":"440_CR57","doi-asserted-by":"publisher","first-page":"6824","DOI":"10.1128\/AAC.01490-15","volume":"59","author":"HR Lapointe","year":"2015","unstructured":"Lapointe HR, Dong W, Lee GQ, Bangsberg DR, Martin JN, Mocello AR, Boum Y, Karakas A, Kirkby D, Poon AF, et al. HIV drug resistance testing by high-multiplex \u201cwide\u201d sequencing on the MiSeq instrument. Antimicrob Agents Chemother. 2015;59:6824\u201333.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR58","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1128\/AAC.01345-09","volume":"54","author":"EC Reuman","year":"2010","unstructured":"Reuman EC, Bachmann MH, Varghese V, Fessel WJ, Shafer RW. Panel of prototypical raltegravir-resistant infectious molecular clones in a novel integrase-deleted cloning vector. Antimicrob Agents Chemother. 2010;54:934\u20136.","journal-title":"Antimicrob Agents Chemother"},{"key":"440_CR59","doi-asserted-by":"publisher","first-page":"F9","DOI":"10.1097\/01.aids.0000232228.88511.0b","volume":"20","author":"BG Brenner","year":"2006","unstructured":"Brenner BG, Oliveira M, Doualla-Bell F, Moisi DD, Ntemgwa M, Frankel F, Essex M, Wainberg MA. HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture. AIDS. 2006;20:F9\u201313.","journal-title":"AIDS"},{"key":"440_CR60","doi-asserted-by":"publisher","first-page":"F1","DOI":"10.1097\/00002030-200301030-00001","volume":"17","author":"B Brenner","year":"2003","unstructured":"Brenner B, Turner D, Oliveira M, Moisi D, Detorio M, Carobene M, Marlink RG, Schapiro J, Roger M, Wainberg MA. A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS. 2003;17:F1\u20135.","journal-title":"AIDS"},{"key":"440_CR61","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1097\/QAD.0b013e32835d9f6d","volume":"27","author":"EL Asahchop","year":"2013","unstructured":"Asahchop EL, Wainberg MA, Oliveira M, Xu H, Brenner BG, Moisi D, Ibanescu IR, Tremblay C. Distinct resistance patterns to etravirine and rilpivirine in viruses containing nonnucleoside reverse transcriptase inhibitor mutations at baseline. AIDS. 2013;27:879\u201387.","journal-title":"AIDS"},{"key":"440_CR62","doi-asserted-by":"publisher","first-page":"751","DOI":"10.1002\/jmv.22047","volume":"83","author":"BG Brenner","year":"2011","unstructured":"Brenner BG, Lowe M, Moisi D, Hardy I, Gagnon S, Charest H, Baril JG, Wainberg MA, Roger M. Subtype diversity associated with the development of HIV-1 resistance to integrase inhibitors. J Med Virol. 2011;83:751\u20139.","journal-title":"J Med Virol"},{"key":"440_CR63","doi-asserted-by":"publisher","first-page":"2305","DOI":"10.1097\/00002030-200411190-00011","volume":"18","author":"JP Routy","year":"2004","unstructured":"Routy JP, Machouf N, Edwardes MD, Brenner BG, Thomas R, Trottier B, Rouleau D, Tremblay CL, Cote P, Baril JG, et al. Factors associated with a decrease in the prevalence of drug resistance in newly HIV-1 infected individuals in Montreal. AIDS. 2004;18:2305\u201312.","journal-title":"AIDS"}],"container-title":["Retrovirology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-018-0440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12977-018-0440-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12977-018-0440-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T17:00:26Z","timestamp":1661792426000},"score":1,"resource":{"primary":{"URL":"https:\/\/retrovirology.biomedcentral.com\/articles\/10.1186\/s12977-018-0440-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,17]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["440"],"URL":"https:\/\/doi.org\/10.1186\/s12977-018-0440-3","relation":{},"ISSN":["1742-4690"],"issn-type":[{"value":"1742-4690","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,8,17]]},"assertion":[{"value":"5 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 August 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}],"article-number":"56"}}